Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

05. Juli 2018 12:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Receives a €435,000 Translational Research Grant to Develop Precision Medicine Targeting for Tedopi®

Funding through the Eurostars European Programme, led in France by Bpifrance NANTES, France, July 05, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE) today...
02. Juli 2018 02:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Receives IDMC Approval to Continue “Atalante 1” Phase 3 NSCLC Clinical Trial of Tedopi®

Trial in Non-Small Cell Lung Cancer (NSCLC) Patients After Immune Checkpoint Inhibitor FailureCheckpoint Inhibitor Failures Is an Unmet Need in Non-Small Cell Lung Cancer Patient Population NANTES,...
13. Juni 2018 12:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Results of 2018 Annual Shareholder Meeting

NANTES, France, June 13, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE) announces that all the resolutions submitted to a vote at the Combined General...
17. Mai 2018 12:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics to Present at 4th Annual Immuno-Oncology: BD&L and Investment Forum

Forum to be held in Chicago, IL, on June 1, 2018 NANTES, France, May 17, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN:FR0012127173) (Mnémo:OSE) today announces that Alexis Peyroles, chief...
07. Mai 2018 02:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Presents New Data on OSE-127 at the American Association of Immunologists (AAI) Annual Meeting May 4-8 2018 in Austin, Texas

OSE-127 significantly decreases inflammation in colon biopsies from patients with inflammatory bowel diseases and enhances regulatory T-lymphocytes, the cells that fight inflammation.In patients with...
23. April 2018 12:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Receives the EuroNext Tech40 Label

NANTES, France, April 23, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173) (Mnémo:OSE) has received the EuroNext Tech40 Label and is thus admitted to the “Tech40” index. Wanting...
12. April 2018 12:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Evolution in Company’s Board of Directors and Management

Dominique Costantini, MD, Appointed as Chairman of Company’s Board of Directors, Alexis Peyroles Appointed as Chief Executive OfficerNatural, Seamless Evolution Follows Three Structuring License...
05. April 2018 01:30 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics to Host Conference Call on April 5, 2018 to Discuss Boehringer Ingelheim Global Immuno-Oncology Partnership

NANTES, France, April 05, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN:FR0012127173) (Mnémo:OSE), today announced that it will host an audio/web conference to discuss its global...
04. April 2018 12:00 ET | Quelle: OSE Immunotherapeutics

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

Boehringer Ingelheim and OSE Immunotherapeutics enter into a global license and collaboration agreement in immuno-oncology to develop OSE-172, a novel checkpoint inhibitor antibody targeting myeloid...
28. März 2018 12:07 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics: 2017 Annual Results and Clinical Advances of its Proprietary and Partnered Products

Key Clinical Portfolio Development Progress Planned for 2018 Tedopi® (neoepitopes): Phase 3 clinical trial in NSCLC – Redeployment in the U.S., Europe and Israel, based on a revised...

Vorherige Seite